Osteochondromas – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032
Osteochondroma can manifest as a
singular abnormal growth or as part of multiple osteochondromas in individuals
with multiple hereditary exostoses (HME). Its symptoms include a painless
protrusion near the joints, pain experienced during physical activity,
sensations of numbness or tingling, and alterations in blood flow. Solitary
osteochondromas can be categorized into primary and secondary forms based on
their causes. Primary osteochondromas develop spontaneously without any
identifiable triggering event. In contrast, secondary osteochondromas can arise
from childhood exposure to radiation or trauma (such as surgery or
Salter-Harris fractures). The prevalence of post-radiation osteochondromas
ranges from 6% to 24%, making them the most common benign tumors induced by
radiation. The period between radiation exposure and the development of
osteochondromas can range from 3 to 17 years. In patients with HME, surgical
intervention is more frequently required due to an increased risk of malignant transformation
and more severe deformities in the bone structure. Surgical procedures may be
performed to correct or improve associated bone deformities. On average,
patients with HME undergo 2.7 surgical procedures. When diagnosing
osteochondroma, it is necessary to consider both benign and malignant growths
as potential differential diagnoses. These may include Subungual Exostosis,
Dysplasia Epiphysealis Hemimelica, Turret Exostosis, Bizarre Parosteal
Osteochondromatous Proliferation, Parosteal Osteosarcoma, Juxtacortical
Chondroma, Subperiosteal Hematoma. The prognosis for the solitary form of
osteochondroma is generally favorable, with malignant transformation occurring
in only 1% of patients. The majority of solitary lesions are small and do not
cause symptoms. Potential complications can include fractures, compression of
nearby nerves and blood vessels, and the formation of bursae. Symptomatic
lesions can be treated through surgical excision, although this procedure
carries risks of recurrence, nerve and blood vessel injuries, and compartment
syndrome. The complications associated with osteochondroma can range from minor
cosmetic concerns to severe neurological complications and malignant
transformation.
·
In the USA, the incidence of osteochondromas
is estimated to be 0.44 per 100,000).
Thelansis’s “Osteochondromas Market
Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022
To 2032" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Osteochondromas treatment modalities
options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan,
and China).
KOLs insights
of Osteochondromas across 8 MM market from the centre of Excellence/ Public/
Private hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Osteochondromas Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment